CASI Pharmaceuticals logo
CASI Pharmaceuticals CASI

Quarterly report 2022-Q3
added 11-14-2022

report update icon

CASI Pharmaceuticals Income Statement 2011-2026 | CASI

Annual Income Statement CASI Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.09 B 371 M 285 M 300 M 255 M 74.3 M 35 M 45.5 M 49.9 M 39.6 M 28.2 M

Shares

136 M 110 M 95.9 M 84.8 M 61.5 M 55.9 M 32.4 M 28.6 M 26.1 M 19.1 M 11.8 M

Historical Prices

8.4 24.6 17.7 32.8 34.6 14.2 7.9 16.2 18.9 29.5 20.7

Net Income

-36.7 M -48.3 M -46 M -27.5 M -10.8 M -9.45 M -7.21 M -26.2 M -5.74 M -14.5 M -4.56 M

Revenue

30.2 M 15.1 M 4.13 M - - - 47.7 K 23.7 K - 669 K 1.94 M

Cost of Revenue

12.6 M 9.51 M 3.94 M - - - - - - - -

Gross Profit

17.6 M 5.63 M 196 K - - - 41.4 K 16.3 K - 669 K 1.94 M

Operating Income

-41.8 M -51.5 M -47 M -27.2 M - - - - - - -

Interest Expense

2.9 K 3.1 K 5.6 K 7.5 K 7.5 K -26.1 K -81.5 K -26.6 K 1.66 K 10 M -

EBITDA

-41.4 M -30.1 M -37.8 M -24.8 M -10.6 M -9.35 M -7.08 M -6.46 M -5.72 M -4.48 M -4.53 M

Operating Expenses

- 38.9 M 40.2 M 26.5 M 10.8 M 9.42 M 7.19 M 6.52 M 5.74 M 5.17 M 6.51 M

General and Administrative Expenses

23.8 M 19.7 M 27.3 M 18 M 3.16 M 4.78 M 3.12 M 3.76 M 2.99 M 2.8 M 3.05 M

All numbers in USD currency

Quarterly Income Statement CASI Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 13.6 M 13.6 M 138 M 14 M 14 M 14 M 125 M 124 M 118 M 101 K 98.8 K 97.8 M 95.9 K 95.7 K 95.6 K 95.3 M 81.5 K 86 M 71.2 M 69.8 M 60.2 M 60.2 M 60.2 M - 49.2 M 42.9 M 40.2 M - 32.4 M 32.4 M 32.4 M - 27.8 M 27 M 27 M 27.1 M 27 M 27 M 23.4 M 22.6 M 22.5 M 19 M 12.2 M 12.2 M 12 M 11.5 M 12.2 M

Net Income

- -5.2 M -7.68 M -8.6 M - -10.2 M -6.95 M -13.9 M - -17 M -8.69 M -8.44 M - -9.89 M -15.5 M -8.18 M - -8.76 M -5.86 M -3.59 M - -1.61 M -2.41 M -1.7 M - -1.69 M -3.29 M -1.79 M - -1.6 M -2.1 M -1.8 M - -21.5 M -1.62 M -1.45 M - -1.44 M -1.85 M -1.14 M - -1.19 M -10.5 M -2.53 M - -1.31 M -1.66 M -2.6 M

Revenue

- 10.2 M 8.57 M 9.06 M - 8.11 M 7.16 M 5.74 M - 4.24 M 2.67 M 3.41 M - 2.79 M - - - - - - - - - - - - - - - - 24 K 23.7 K - - - - - - - - - - - - - - 8.85 K -

Cost of Revenue

- 4.25 M 3.55 M 3.76 M - 3.42 M 2.98 M 2.36 M - 1.83 M 2.52 M 3.21 M - 2.65 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 5.97 M 5.02 M 5.3 M - 4.7 M 4.18 M 3.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -6.35 M -7.75 M -7.29 M - -6.89 M -7.98 M -15.6 M - -18.7 M -8.89 M -8.77 M - -10.6 M -15.8 M -8.32 M - -8.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 11 K 11 K 38 K - 487 K 33 K 1 M - 1.2 K 700 190 K - 414 K 320 K 49 K - 11 K 13.1 K 6.73 K - -546 -72 142 - -5.61 K -8.76 K -8.77 K - -24.3 K -24.3 K -24.2 K - -2.93 K 129 384 - 408 443 -390 - - 9.17 M 876 K - - - -

EBITDA

- -5.79 M -7.64 M -7.2 M - -6.5 M -7.67 M -15.4 M - -18.3 M -8.61 M -8.62 M - -10.1 M -15.2 M -8.19 M - -8.46 M 142 K 65.8 K - 69.4 K 37.9 K 18.5 K - 48 K 32.5 K 19 K - 50.8 K 33.2 K 16.5 K - 32.7 K 19.2 K 6.53 K - 12.9 K 9.04 K 4.66 K - 15.1 K 9.38 K 4.23 K - 33.6 K 23.7 K 12.1 K

General and Administrative Expenses

- 4.85 M 5.52 M 5.32 M - 5.26 M 5.49 M 5.5 M - 5.35 M 4.08 M 4.06 M - 7.98 M 6.98 M 5.71 M - 6.9 M 4.04 M 1.3 M - 626 K 691 K 644 K - 677 K 1.91 M 765 K - 674 K 858 K 925 K - 1.15 M 892 K 891 K - 663 K 1.02 M 630 K - 565 K 602 K 1.1 M - 557 K 720 K 1.25 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company CASI Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.55 -0.28 % $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 3.26 4.15 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 0.05 % $ 4.31 M chinaChina
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.14 -1.9 % $ 105 M schweizSchweiz
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.55 -1.16 % $ 179 M israelIsrael
argenx SE argenx SE
ARGX
$ 711.17 1.12 % $ 25 B niderlandNiderland
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.43 -4.99 % $ 8.25 B australiaAustralia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 230.22 -0.35 % $ 5 B danmarkDanmark
BioCardia BioCardia
BCDA
$ 1.3 1.97 % $ 27.5 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.12 1.16 % $ 499 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.43 -4.19 % $ 7.46 B israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.3 -2.46 % $ 1.01 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.59 1.6 % $ 214 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.4 -2.04 % $ 917 K usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.63 -0.57 % $ 16.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.52 0.33 % $ 388 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 94.73 4.62 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA